BioMarin Pharmaceutical (XTRA:BM8) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BM8 Panoramica delle azioni

Develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

Informazioni sull'azienda

BM8 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	5/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Trading at 61.1% below our estimate of its fair value

Earnings are forecast to grow 34.05% per year

Earnings grew by 75.2% over the past year

Analisi del rischio

Shares are highly illiquid

BioMarin Pharmaceutical Inc. Concorrenti

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€930.5m

SCHOTT Pharma KGaA

XTRA:1SXP

€4.6b

Merck KGaA

XTRA:MRK

€69.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per BioMarin Pharmaceutical
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$81.02
Massimo di 52 settimane	US$97.73
Minimo di 52 settimane	US$72.40
Beta	0.31
1Variazione di 1 mese	0%
Variazione a 3 mesi	-0.12%
Variazione di 1 anno	-19.25%
3Variazione a 3 anni	22.24%
Variazione a 5 anni	n/a
Variazione dall'IPO	575.17%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	BM8	DE Biotechs	DE Mercato
7D	0%	1.0%	1.5%
1Y	-19.3%	-15.4%	12.6%

Ritorno vs Industria: BM8 exceeded the German Biotechs industry which returned -23.6% over the past year.

Rendimento vs Mercato: BM8 underperformed the German Market which returned -1.4% over the past year.

Volatilità dei prezzi

Is BM8's price volatile compared to industry and market?
BM8 volatility
BM8 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.7%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: BM8 has not had significant price volatility in the past 3 months.

Volatilità nel tempo: Insufficient data to determine BM8's volatility change over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1996	3,082	Alexander Hardy	www.biomarin.com

BioMarin Pharmaceutical Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di BioMarin Pharmaceutical con la sua capitalizzazione di mercato?
BM8 statistiche fondamentali
Capitalizzazione di mercato	€15.44b
Guadagni(TTM)	€135.94m
Ricavi(TTM)	€2.14b

113.6x

Rapporto P/E

7.2x

Rapporto P/S

BM8 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BM8 Conto economico (TTM)
Ricavi	US$2.31b
Costo del fatturato	US$1.22b
Profitto lordo	US$1.09b
Altre spese	US$943.60m
Guadagni	US$147.02m

Ultimi guadagni dichiarati

Sep 30, 2023

Prossima data di guadagno

Feb 22, 2024

Utile per azione (EPS)	0.78
Margine lordo	47.20%
Margine di profitto netto	6.36%
Rapporto debito/patrimonio netto	22.2%

Come si è comportato BM8 nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

BM8 Panoramica delle azioni

Premi

Analisi del rischio

BioMarin Pharmaceutical Inc. Concorrenti

XTRA:BIO3

€1.4b

XTRA:FYB

€930.5m

XTRA:1SXP

€4.6b

XTRA:MRK

€69.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Recent updates

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Biomarin Pharmaceutical Inc. Announces CEO Changes

Third quarter 2023 earnings released: EPS: US$0.21 (vs US$0.036 loss in 3Q 2022)

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe

Executive VP recently sold €899k worth of stock

Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.15 in 2Q 2022)

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc

U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program

Full year 2022 earnings released: EPS: US$0.76 (vs US$0.35 loss in FY 2021)

BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023

Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis

BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its Type II Variation Application to Extend the Indication for VOXZOGO® (Vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 2

BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program

BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022

FDA Accepts Biomarin's Biologics License Application (Bla) for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Report Q3, 2022 Results on Oct 26, 2022

BioMarin Pharmaceutical Inc. Announces First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN(TM) (valoctocogene roxaparvovec), Approved by European Commission (EC)

Insider recently sold €586k worth of stock

Second quarter 2022 earnings released: EPS: US$0.15 (vs US$0.071 in 2Q 2021)

Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2022

BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed

BioMarin Pharmaceutical Inc. Announces Favorable Results from Global Phase 2 Study of Voxzogo™ (Vosoritide) for Injection in Infants and Young Children with Achondroplasia At the Endocrine Society Annual Meeting

BioMarin Pharmaceutical Inc. Announces Durable Hemostatic Efficacy Maintained over 6 Years in Ongoing Phase 1 2 Study of Valoctocogene Roxaparvovec

BioMarin Pharmaceutical Inc. Announces Executive Appointments

First quarter 2022 earnings released: EPS: US$0.66 (vs US$0.096 in 1Q 2021)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2022

BioMarin Pharmaceutical Inc., Annual General Meeting, May 24, 2022

Independent Director recently sold €446k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year of 2022

BioMarin Pharmaceutical Inc. Provides Updates on Progress in Gene Therapy Programs

BioMarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control in the Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At Two Year Analysis

ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action

Chairman & CEO recently sold €116k worth of stock

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$4.33 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.16 loss in 2Q 2020)

BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

European Medicines Agency Validates Biomarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Midcap Growth Index

BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

Independent Director Michael Grey has left the company

European Medicines Agency Grants BioMarin Pharmaceutical Inc.'s Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A

BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A

BioMarin Pharmaceutical Inc. Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting